Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 12:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 843 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo equivalent Clear all

Conditions: Idiopathic Hypersomnia
Interventions: FT218, Placebo; Drug · Other
Lead sponsor: Avadel; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 7
States / cities: Boulder, Colorado • Winter Park, Florida • Stockbridge, Georgia + 4 more

Conditions: Headache
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Obsessive-Compulsive Disorder, Tic Disorders, Tourette Syndrome
Interventions: Ondansetron, Placebo; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 60 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: New York, New York

Conditions: Postmenopausal Female Patients, Vasomotor Symptoms, Menopausal Hormone Therapy
Interventions: Moderate Intensity Exercise (MIE), High intensity exercise (HIE), Control (No exercise); Other
Lead sponsor: University of Virginia; Other
Eligibility: 45 Years to 75 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Sepsis, Severe, Septic Shock
Interventions: Ascorbic Acid, Thiamine, Hydrocortisone, Sodium Chloride 0.9%; Drug
Lead sponsor: Community Medical Center, Toms River, NJ; Other
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Lakewood, New Jersey • Toms River, New Jersey

Conditions: Hypertension
Interventions: clevidipine, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 15
States / cities: Mobile, Alabama • Los Angeles, California • Pasadena, California + 11 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Sepsis
Interventions: IVIG, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: Up to 72 Hours
Enrollment: 2,416 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1988 – 1991
U.S. locations: 8
States / cities: Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone Bromide, Placebo-Normal Saline; Drug
Lead sponsor: St. John Health System, Michigan; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Southfield, Michigan

Conditions: Asthma
Interventions: QBX258, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 15
States / cities: Anaheim, California • Riverside, California • Rolling Hills Estates, California + 11 more

Conditions: COVID-19
Interventions: Placebo, Remdesivir; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 41
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 35 more

Conditions: Autism Spectrum Disorders
Interventions: Syntocinon (synthetic oxytocin), Placebo; Drug · Other
Lead sponsor: University of Minnesota; Other
Eligibility: 12 Years to 17 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 58
States / cities: Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more

Conditions: Parkinson's Disease (Disorder)
Interventions: IR CD-LD, IPX203 ER CD-LD, Placebo Matching IPX203, Placebo Matching IR CD-LD; Drug · Other
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 40 Years and older
Enrollment: 630 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 46 more

Conditions: Hereditary Angioedema
Interventions: rhC1INH, Placebo (Saline); Drug
Lead sponsor: Pharming Technologies B.V.; Industry
Eligibility: 13 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 15
States / cities: Scottsdale, Arizona • Granada Hills, California • Los Angeles, California + 12 more

Conditions: COVID-19
Interventions: Placebo, Remdesivir, Risankizumab; Other · Drug · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 214 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 32
States / cities: Tucson, Arizona • Bakersfield, California • Newport Beach, California + 26 more

Conditions: Premature Birth
Interventions: Betamethasone - ACTIVE, Normal Saline - PLACEBO; Drug · Other
Lead sponsor: Pediatrix; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 9
States / cities: Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 6 more

Conditions: Metabolic Syndrome, Insulin Resistance, DNA Damage
Interventions: Blueberry Powder, Placebo; Dietary Supplement
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 30 Years to 60 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: Hypercholesterolemia
Interventions: Inclisiran, Ezetimibe, Matching Placebo for Inclisiran, Matching Placebo for Ezetimibe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Dothan, Alabama • DeLand, Florida + 19 more

Conditions: Ischemia Reperfusion Injury
Interventions: recombinant P-selectin glycoprotein ligand Ig fusion protein, Viaspan® and saline; Drug
Lead sponsor: Y's Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions: Baclofen, Placebo; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Major Depressive Disorder
Interventions: SAGE-217, Placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 46
States / cities: Bentonville, Arkansas • Bellflower, California • Garden Grove, California + 40 more

Conditions: Opioid Dependence
Interventions: Memantine, Naltrexone; Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: AL Amyloidosis
Interventions: CAEL-101, Placebo, cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen; Drug · Other
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 32
States / cities: Scottsdale, Arizona • Duarte, California • Palo Alto, California + 26 more

Conditions: Longevity, GLP-1, Geroscience, Aging
Interventions: Metformin, Rapamycin, Naltrexone, Vitamin C; Drug · Dietary Supplement
Lead sponsor: AgelessRx; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)

Ketamine for Acute Migraine in the Emergency Department

Effects of Ondansetron in Obsessive-compulsive and Tic Disorders

Exercise Training Intensity and Nitrate Supplementation in Post-Menopausal Females on Hormone Therapy

Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis.

Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2)

Intravenous Immune Globulin (IVIG) to Prevent Neonatal Infection

Methylnaltrexone for Treatment of Opiate-Induced Constipation in the Intensive Care Unit

A Study to Establish the Efficacy of QBX258 in Patients With Moderate to Severe Asthma

Adaptive COVID-19 Treatment Trial (ACTT)

Intranasal Oxytocin and Learning in Autism

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations

Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks

ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

Impact of a Booster Course of Antenatal Steroids on Neonatal Outcome in Patients With Premature Rupture of the Membranes

Effect of Blueberry Consumption on Metabolic Syndrome & DNA Damage

Efficacy and Safety of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-lowering Therapy.

YSPSL for Prevention of Ischemic Reperfusion Injury in Patients Undergoing Cadaveric Orthotopic Liver Transplantation

Baclofen Effects on Smoking Urge and Withdrawal

A Study to Evaluate SAGE-217 for Prevention of Relapse in Adult Participants With Major Depressive Disorder

Memantine and Naltrexone Treatment for Opioid Dependence

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation